rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2018-746-752rsp-2652Research ArticleПРОГРАММА НЕПРЕРЫВНОГО ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ВРАЧЕЙPOSTGRADUATE PROGRAM OF CONTINUING MEDICAL EDUCATIONСовременная стратегия лечения болезни депонирования кристаллов пирофосфата кальцияCurrent strategy in the treatment of calcium pyrophosphate crystal deposition diseaseВладимировС. А.VladimirovS. A.

научный сотрудник лаборатории микрокристаллических артритов.

Москва, Россия 115522 Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

ser_vlad@mail.ruЕлисеевМ. С.EliseevM. S.

заведующий лабораторией микрокристаллических артритов.

Москва, Россия 115522 Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой».РоссияV.A. Nasonova Research Institute of Rheumatology.Russian Federation201821012019566746752Copyright © Владимиров С.А., Елисеев М.С., 20192019Владимиров С.А., Елисеев М.С.Vladimirov S.A., Eliseev M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2652

Рассмотрены современные средства для лечения болезни депонирования кристаллов пирофосфата кальция. Обсуждены преимущества и недостатки наиболее широко применяемых медикаментов: нестероидных противовоспалительных препаратов, колхицина, глюкокортикоидов, традиционных иммунодепрессантов, перспективы применения генно-инженерных биологических препаратов.

The paper considers currently available drugs used to treat calcium pyrophosphate crystal deposition disease. It discusses the advantages and disadvantages of the most widely used drugs, such as  nonsteroidal anti-inflammatory drugs, colchicine, glucocorticoids, traditional immunosuppressants, as well as prospects for the use of biologic agents.

болезнь депонирования кристаллов пирофосфата кальцияколхицинметотрексатглюкокортикоидыcalcium pyrophosphate crystal deposition diseasecolchicinemethotrexateglucocorticoidsReferencesHollander JL, Jessar RA, McCarty DJ. Synovianalysis: an aid in arthritis diagnosis. Bull Rheum Dis. 1961;(12):263-4.Hollander JL, Jessar RA, McCarty DJ. Synovianalysis: an aid in arthritis diagnosis. Bull Rheum Dis. 1961;(12):263-4.Кудаева ФМ, Владимиров СА, Елисеев МС и др. Особенности клинических проявлений болезни депонирования кристаллов пирофоасфата кальция. Научно-практическая ревматология. 2014;52(4):405-9 [Kudaeva FM, Vladimirov SA, Eliseev MS, et al. The clinical manifestations of calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):405-9 (In Russ.)]. doi: 10.14412/1995-4484-2014-405-409Кудаева ФМ, Владимиров СА, Елисеев МС и др. Особенности клинических проявлений болезни депонирования кристаллов пирофоасфата кальция. Научно-практическая ревматология. 2014;52(4):405-9 [Kudaeva FM, Vladimirov SA, Eliseev MS, et al. The clinical manifestations of calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):405-9 (In Russ.)]. doi: 10.14412/1995-4484-2014-405-409Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48:711-5. doi: 10.1093/rheumatology/kep081Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48:711-5. doi: 10.1093/rheumatology/kep081Doherty M. Calcium pyrophosphate dihydrate crystal-associated arthropathy. In: Hochberg M, ed. Rheumatology. Edinburgh: Mosby; 2003. P. 1937-50Doherty M. Calcium pyrophosphate dihydrate crystal-associated arthropathy. In: Hochberg M, ed. Rheumatology. Edinburgh: Mosby; 2003. P. 1937-50Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62:513-8. doi: 10.1136/ard.62.6.513Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62:513-8. doi: 10.1136/ard.62.6.513Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol. 1989;16(9):1241-5.Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol. 1989;16(9):1241-5.Sanmarti R, Panella D, Brancos MA, et al. Prevalence of articular chondrocalcinosis in elderly subjects in a rural area of Catalonia. Ann Rheum Dis. 1993;52:418-22. doi: 10.1136/ard.52.6.418Sanmarti R, Panella D, Brancos MA, et al. Prevalence of articular chondrocalcinosis in elderly subjects in a rural area of Catalonia. Ann Rheum Dis. 1993;52:418-22. doi: 10.1136/ard.52.6.418Saadeh C. Calcium Pyrophosphate Deposition Disease. Medscape, 09.2009. Доступно по ссылке:Saadeh C. Calcium Pyrophosphate Deposition Disease. Medscape, 09.2009. Доступно по ссылке:https://emedicine.medscape.com/article/330936-overviewhttps://emedicine.medscape.com/article/330936-overviewSalaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23:819-28.Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23:819-28.Елисеев МС, Владимиров СА. Распространенность и клинические особенности подагры и болезни депонирования пирофосфата кальция у пациентов с острым артритом. Научно-практическая ревматология. 2015;53(4):375-8 [Eliseev MS, Vladimirov SA. The prevalence and clinical features of gout and calcium pyrophosphate deposition disease in patients with acute arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;53(4):375-8 (In Russ.)]. doi: 10.14412/1995-4484-2015-375-378Елисеев МС, Владимиров СА. Распространенность и клинические особенности подагры и болезни депонирования пирофосфата кальция у пациентов с острым артритом. Научно-практическая ревматология. 2015;53(4):375-8 [Eliseev MS, Vladimirov SA. The prevalence and clinical features of gout and calcium pyrophosphate deposition disease in patients with acute arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;53(4):375-8 (In Russ.)]. doi: 10.14412/1995-4484-2015-375-378Zhang W, Doherty M, Bardin T, Barskova V, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563-70. doi: 10.1136/ard.2010.139105Zhang W, Doherty M, Bardin T, Barskova V, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563-70. doi: 10.1136/ard.2010.139105Rosenthal AK, Ryan LM. Crystal arthritis: calcium pyrophosphate deposition-nothing ‘pseudo’ about it! Nat Rev Rheumatol. 2011;7(5):257-8. doi: 10.1038/nrrheum.2011.50Rosenthal AK, Ryan LM. Crystal arthritis: calcium pyrophosphate deposition-nothing ‘pseudo’ about it! Nat Rev Rheumatol. 2011;7(5):257-8. doi: 10.1038/nrrheum.2011.50Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;6:29-42. doi: 10.1136/annrheumdis-2016-209707Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;6:29-42. doi: 10.1136/annrheumdis-2016-209707Sivera F, Andres M, Pascual E. Current advances in therapies for calcium pyrophosphate crystal arthritis. Curr Opin Rheumatol. 2016;28(2):140-4. doi: 10.1097/BOR.0000000000000252Sivera F, Andres M, Pascual E. Current advances in therapies for calcium pyrophosphate crystal arthritis. Curr Opin Rheumatol. 2016;28(2):140-4. doi: 10.1097/BOR.0000000000000252Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis. 1983;42:106-7. doi: 10.1136/ard.42.Suppl_1.106Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis. 1983;42:106-7. doi: 10.1136/ard.42.Suppl_1.106Ritter K, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994;21(4):696-9.Ritter K, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994;21(4):696-9.Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine. 2014;81(1):98-100. doi: 10.1016/j.jbspin.2013.05.006Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine. 2014;81(1):98-100. doi: 10.1016/j.jbspin.2013.05.006Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendation for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-24. doi: 10.1136/ard.2006.055269Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendation for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-24. doi: 10.1136/ard.2006.055269Terkeltaub RA, Furst DE, Bennett K, et al. High-vs low-dosing of oral colchicine for early acute gout flare: Twenty-four hour outcome results of the first randomized, placebocontrolled, dose comparison colchicine trial. Arthritis Rheum. 2010 Apr;62(4):1060-8. doi: 10.1002/art.27327Terkeltaub RA, Furst DE, Bennett K, et al. High-vs low-dosing of oral colchicine for early acute gout flare: Twenty-four hour outcome results of the first randomized, placebocontrolled, dose comparison colchicine trial. Arthritis Rheum. 2010 Apr;62(4):1060-8. doi: 10.1002/art.27327Announ N, Guerne P-A. Treating diffilt crystal pyrophosphate dihydrate deposition disease. Curr Rheumatol Rep. 2008;10(3):228-34. doi: 10.1007/s11926-008-0037-2Announ N, Guerne P-A. Treating diffilt crystal pyrophosphate dihydrate deposition disease. Curr Rheumatol Rep. 2008;10(3):228-34. doi: 10.1007/s11926-008-0037-2Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986;13(4):804-5.Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986;13(4):804-5.Das SK, Mishra K, Ramakrishnah S, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthr Cartilage. 2002;10:247-52. doi: 10.1053/joca.2002.0516Das SK, Mishra K, Ramakrishnah S, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthr Cartilage. 2002;10:247-52. doi: 10.1053/joca.2002.0516Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415-22 doi: 10.1016/j.amjmed.2017.06.028Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415-22 doi: 10.1016/j.amjmed.2017.06.028Елисеев МС, Желябина ОВ. Сочетание подагры и болезни депонирования пирофосфатов кальция: трудности диагностики и лечения. РМЖ. Медицинское обозрение. 2017;(1):44-7 [Eliseev MS, Zhelyabina OV. The combination of gout and the disease of calcium pyrophosphate deposition: the difficulties of diagnosis and treatment. RMZh. Meditsinskoe Obozrenie. 2017;(1):44-7 (In Russ.)].Елисеев МС, Желябина ОВ. Сочетание подагры и болезни депонирования пирофосфатов кальция: трудности диагностики и лечения. РМЖ. Медицинское обозрение. 2017;(1):44-7 [Eliseev MS, Zhelyabina OV. The combination of gout and the disease of calcium pyrophosphate deposition: the difficulties of diagnosis and treatment. RMZh. Meditsinskoe Obozrenie. 2017;(1):44-7 (In Russ.)].Елисеев МС, Владимиров СА. Применение мелоксикама (Амелотекс®) у больных пирофосфатной артропатией. Cовременная ревматология. 2011;5(3):34-6 [Eliseev MS, Vladimirov SA. Use of meloxicam (Amelotex®) in patients with pyrophosphate arthropathy. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2011;5(3):34-7 (In Russ.)]. doi: 10.14412/1996-7012-2011-682Елисеев МС, Владимиров СА. Применение мелоксикама (Амелотекс®) у больных пирофосфатной артропатией. Cовременная ревматология. 2011;5(3):34-6 [Eliseev MS, Vladimirov SA. Use of meloxicam (Amelotex®) in patients with pyrophosphate arthropathy. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2011;5(3):34-7 (In Russ.)]. doi: 10.14412/1996-7012-2011-682Andres M, Sivera F, Pascual E. Therapy for CPPD: Options and Evidence. Curr Rheumatol Rep. 2018 Apr 19;20(6):31. doi: 10.1007/s11926-018-0739-zAndres M, Sivera F, Pascual E. Therapy for CPPD: Options and Evidence. Curr Rheumatol Rep. 2018 Apr 19;20(6):31. doi: 10.1007/s11926-018-0739-zRosenthal AK. Update in calcium deposition diseases. Curr Opin Rheumatol. 2007;19(2):158-62. doi: 10.1097/BOR.0b013e3280145289Rosenthal AK. Update in calcium deposition diseases. Curr Opin Rheumatol. 2007;19(2):158-62. doi: 10.1097/BOR.0b013e3280145289Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed. 1996;63(4):248-54.Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Rev Rhum Engl Ed. 1996;63(4):248-54.Roane DW, Harris MD, Carpenter MT, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997;24(6):1168-70.Roane DW, Harris MD, Carpenter MT, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997;24(6):1168-70.Potvin F, Petitclerc E, Marceau F. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J Immun. 1997;158:1872-9.Potvin F, Petitclerc E, Marceau F. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J Immun. 1997;158:1872-9.Rothschild B, Yakubov LE. Prospective 6-month, doubleblind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997 May;23(5):327-31.Rothschild B, Yakubov LE. Prospective 6-month, doubleblind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997 May;23(5):327-31.Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56:688-92. doi: 10.1002/art.22389Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56:688-92. doi: 10.1002/art.22389Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012;18:234-6. doi: 10.1097/RHU.0b013e3182611471Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012;18:234-6. doi: 10.1097/RHU.0b013e3182611471Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008;58:2210-1. doi: 10.1002/art.23552Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008;58:2210-1. doi: 10.1002/art.23552Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16:458. doi: 10.1186/s13075-014-0458-4Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16:458. doi: 10.1186/s13075-014-0458-4Pascual E, Andres M, Sivera F. Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease? Arthritis Res Ther. 2015 Apr 1;17:89. doi: 10.1186/s13075-015-0598-1Pascual E, Andres M, Sivera F. Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease? Arthritis Res Ther. 2015 Apr 1;17:89. doi: 10.1186/s13075-015-0598-1Theiler G, Quehenberger F, Rainer F, et al. The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation. Rheumatol Int. 2014;34:137-9. doi: 10.1007/s00296-012-2608-9Theiler G, Quehenberger F, Rainer F, et al. The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation. Rheumatol Int. 2014;34:137-9. doi: 10.1007/s00296-012-2608-9Oliviero F, Scanu A, Galozzi P, et al. Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine. 2013;80:287-90. doi: 10.1016/j.jbspin.2012.08.006Oliviero F, Scanu A, Galozzi P, et al. Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine. 2013;80:287-90. doi: 10.1016/j.jbspin.2012.08.006Елисеев МС, Владимиров СА, Насонов ЕЛ. Применение метотрексата у больных с болезнью депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(2):196-201 [Eliseev MS, Vladimirov SA, Nasonov EL. Use of methotrexate in patients with calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(2):196-201 (In Russ.)]. doi: 10.14412/1995-4484-2018-196-201Елисеев МС, Владимиров СА, Насонов ЕЛ. Применение метотрексата у больных с болезнью депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2018;56(2):196-201 [Eliseev MS, Vladimirov SA, Nasonov EL. Use of methotrexate in patients with calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(2):196-201 (In Russ.)]. doi: 10.14412/1995-4484-2018-196-201Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77 [Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77Елисеев МС, Барскова ВГ, Насонов ЕЛ. Канакинумаб (ингибитор интелейкина 1) – прорыв в возможностях противовоспалительной терапии при подагре. Научно-практическая ревматология. 2013;51(4):428-31 [Eliseev MS, Barskova VG, Nasonov EL. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(4):428-31 (In Russ.)]. doi: 10.14412/1995-4484-2013-1255Елисеев МС, Барскова ВГ, Насонов ЕЛ. Канакинумаб (ингибитор интелейкина 1) – прорыв в возможностях противовоспалительной терапии при подагре. Научно-практическая ревматология. 2013;51(4):428-31 [Eliseev MS, Barskova VG, Nasonov EL. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(4):428-31 (In Russ.)]. doi: 10.14412/1995-4484-2013-1255Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374:2575-84. doi: 10.1056/NEJMra1511117Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374:2575-84. doi: 10.1056/NEJMra1511117McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58:631-3. doi: 10.1002/art.23119McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58:631-3. doi: 10.1002/art.23119Announ N, Palmer G, Guerne PA, Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009;76:424-6. doi: 10.1016/j.jbspin.2009.01.001Announ N, Palmer G, Guerne PA, Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009;76:424-6. doi: 10.1016/j.jbspin.2009.01.001Couderc M, Mathieu S, Glace B, Soubrier M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine. 2012;79:330-1. doi: 10.1016/j.jbspin.2011.12.017Couderc M, Mathieu S, Glace B, Soubrier M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine. 2012;79:330-1. doi: 10.1016/j.jbspin.2011.12.017Molto A, Ea HK, Richette P, et al. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012;79:621-3. doi: 10.1016/j.jbspin.2012.01.010Molto A, Ea HK, Richette P, et al. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012;79:621-3. doi: 10.1016/j.jbspin.2012.01.010Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol. 2012;18:310-1. doi: 10.1097/RHU.0b013e31826149a2Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol. 2012;18:310-1. doi: 10.1097/RHU.0b013e31826149a2Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013;80:178-82. doi: 10.1016/j.jbspin.2012.07.018Ottaviani S, Brunier L, Sibilia J, et al. Efficacy of anakinra in calcium pyrophosphate crystal induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013;80:178-82. doi: 10.1016/j.jbspin.2012.07.018Aouba A, Deshayes S, Frenzel L, et al. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediat Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173Aouba A, Deshayes S, Frenzel L, et al. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediat Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173Bruges-Armas J, Bettencourt BF, Couto AR, et al. Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up. Case Rep Rheumatol. 2014;2014:536856. doi: 10.1155/2014/536856Bruges-Armas J, Bettencourt BF, Couto AR, et al. Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up. Case Rep Rheumatol. 2014;2014:536856. doi: 10.1155/2014/536856Quilis N, Andres M, Vela P, Pascual E. Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: two cases report. Joint Bone Spine. 2018 May;85(3):377-8. doi: 10.1016/j.jbspin.2017.04.008Quilis N, Andres M, Vela P, Pascual E. Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: two cases report. Joint Bone Spine. 2018 May;85(3):377-8. doi: 10.1016/j.jbspin.2017.04.008Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum. 1989;32:1443-52. doi: 10.1002/anr.1780321114Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum. 1989;32:1443-52. doi: 10.1002/anr.1780321114Danino O, Svetitsky S, Kenigsberg S, et al. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatology (Oxford). 2018 Aug 1;57(8):1472-80. doi: 10.1093/rheumatology/key092Danino O, Svetitsky S, Kenigsberg S, et al. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatology (Oxford). 2018 Aug 1;57(8):1472-80. doi: 10.1093/rheumatology/key092

The authors declare that there are no conflicts of interest present.